Drug Profile
Fluorescent imaging agent - CEA-Leti/NICE Consortium
Alternative Names: LipImage 815Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator CEA-LETI
- Developer NICE Consortium
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Liver-cancer(Diagnosis) in France (Parenteral)
- 03 Jul 2013 CEA-Leti receives grant from bpifrance for Lipimage 815™ development in Liver cancer (diagnosis)
- 03 Jul 2013 Preclinical trials in Liver cancer (diagnosis) in France (Parenteral)